Ligand Pharmaceuticals Enterprise Value:
581.24M for May 20, 2013Ligand Pharmaceuticals Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 20, 2013 | 581.24M |
| May 17, 2013 | 590.14M |
| May 16, 2013 | 563.46M |
| May 15, 2013 | 567.50M |
| May 14, 2013 | 564.47M |
| May 13, 2013 | 564.27M |
| May 10, 2013 | 563.66M |
| May 9, 2013 | 561.64M |
| May 8, 2013 | 566.90M |
| May 7, 2013 | 552.55M |
| May 6, 2013 | 549.52M |
| May 3, 2013 | 553.76M |
| May 2, 2013 | 553.76M |
| May 1, 2013 | 548.51M |
| April 30, 2013 | 576.19M |
| April 29, 2013 | 581.45M |
| April 26, 2013 | 575.38M |
| April 25, 2013 | 590.74M |
| April 24, 2013 | 577.81M |
| April 23, 2013 | 588.72M |
| April 22, 2013 | 590.14M |
| April 19, 2013 | 568.11M |
| April 18, 2013 | 517.18M |
| April 17, 2013 | 521.83M |
| April 16, 2013 | 531.53M |
| April 15, 2013 | 509.50M |
| April 12, 2013 | 548.30M |
| April 11, 2013 | 539.01M |
| April 10, 2013 | 543.66M |
| April 9, 2013 | 536.58M |
| April 8, 2013 | 541.43M |
| April 5, 2013 | 545.48M |
| April 4, 2013 | 548.10M |
| April 3, 2013 | 544.26M |
| April 2, 2013 | 559.42M |
| April 1, 2013 | 558.61M |
| March 28, 2013 | 562.65M |
| March 27, 2013 | 559.02M |
| March 26, 2013 | 551.34M |
| March 25, 2013 | 545.07M |
| March 22, 2013 | 542.85M |
| March 21, 2013 | 517.59M |
| March 20, 2013 | 520.22M |
| March 19, 2013 | 498.79M |
| March 18, 2013 | 487.68M |
| March 15, 2013 | 494.35M |
| March 14, 2013 | 490.91M |
| March 13, 2013 | 465.86M |
| March 12, 2013 | 478.99M |
| March 11, 2013 | 480.41M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
LGND Enterprise Value Benchmarks
| Companies | |
|---|---|
| Medicines | 1.601B |
| GlaxoSmithKline | 165.72B |
| Momenta Pharmaceuticals | 341.77M |
LGND Enterprise Value Rankings
| Overall |
69th percentile 2480 of 8002 |
| Sector |
68th percentile 218 of 684 in Healthcare |
| Industry |
67th percentile 22 of 68 in Drug Manufacturers - Specialty & Generic |
LGND Enterprise Value Range, Past 5 Years
| Minimum | 50.35M | Nov 19 2008 |
| Maximum | 590.74M | Apr 25 2013 |
| Average | 279.47M |
